Kyverna Therapeutics, Inc Common Stock
Quarterly Financials
| Values in thousands | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $2,024 |
Gross Profit | -415 | -515 | -501 | -563 |
EBITDA | -36,365 | -41,552 | -44,109 | -36,899 |
EBIT | -36,780 | -42,067 | -44,610 | -37,462 |
Net Income | -36,787 | -42,081 | -44,635 | -37,489 |
Net Change In Cash | 0 | 0 | 0 | 2,024 |
Free Cash Flow | -43,713 | -32,153 | -44,915 | -37,593 |
Cash | 34,164 | 53,440 | 56,865 | 96,621 |
Basic Shares | 43,415 | 43,225 | 43,215 | 43,214 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $7,025 | $5,656 |
Gross Profit | -2,133 | -1,707 | 7,025 | 5,656 |
EBITDA | -125,202 | -58,472 | -27,777 | -25,761 |
EBIT | -127,335 | -60,179 | -28,828 | -26,347 |
Net Income | -127,477 | -60,366 | -28,893 | -26,350 |
Net Change In Cash | 0 | 0 | 7,025 | 5,656 |
Free Cash Flow | -116,455 | -53,031 | -36,881 | -23,444 |
Cash | 96,621 | 34,647 | 37,735 | 76,067 |
Basic Shares | 38,334 | 673,622 | 25,803 | 25,803 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | -$0.85 |
2025-06-30 | -$0.97 |
2025-03-31 | -$1.03 |
2024-12-31 | -$0.86 |
